Have a feature idea you'd love to see implemented?
Let us know!
ALVR Allovir Inc
Price (delayed)
$0.57
Market cap
$65.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.88
Enterprise value
-$51M
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative
Highlights
Allovir's debt has plunged by 100% from the previous quarter and by 100% YoY
The quick ratio has soared by 56% since the previous quarter
The equity has declined by 38% year-on-year
Key stats
What are the main financial stats of ALVR
Market
Valuations
Earnings
Shares outstanding
115.54M
Market cap
$65.86M
Enterprise value
-$51M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$100.32M
EBITDA
-$95.93M
Free cash flow
-$94.87M
Per share
Balance sheet
Liquidity
EPS
-$0.88
Free cash flow per share
-$0.82
Book value per share
$1.05
Revenue per share
$0
TBVPS
$1.06
Total assets
$122.53M
Total liabilities
$1.41M
Debt
$0
Equity
$121.12M
Working capital
$121.12M
Debt to equity
0
Current ratio
86.78
Quick ratio
86.3
Net debt/EBITDA
1.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-68.1%
Return on equity
-79%
Return on invested capital
-197%
Return on capital employed
-82.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALVR stock price
How has the Allovir stock price performed over time
Intraday
-0.02%
1 week
3.07%
1 month
-26.45%
1 year
-63.46%
YTD
-16.15%
QTD
-29.5%
Financial performance
How have Allovir's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$108.2M
Net income
-$100.2M
Gross margin
N/A
Net margin
N/A
The net income is up by 41% year-on-year and by 29% since the previous quarter
The operating income has grown by 39% YoY and by 28% from the previous quarter
Growth
What is Allovir's growth rate over time
Valuation
What is Allovir stock price valuation
P/E
N/A
P/B
0.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALVR's EPS is up by 48% YoY and by 28% QoQ
The price to book (P/B) is 80% less than the 5-year quarterly average of 2.7 and 23% less than the last 4 quarters average of 0.7
The equity has declined by 38% year-on-year
Efficiency
How efficient is Allovir business performance
Allovir's return on invested capital has shrunk by 61% YoY and by 23% QoQ
ALVR's return on equity is up by 18% since the previous quarter
The return on assets rose by 13% since the previous quarter but it has declined by 6% year-on-year
Dividends
What is ALVR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALVR.
Financial health
How did Allovir financials performed over time
ALVR's total liabilities has dropped by 97% year-on-year and by 87% since the previous quarter
The current ratio has soared by 58% from the previous quarter
Allovir's debt is 100% less than its equity
Allovir's debt has plunged by 100% from the previous quarter and by 100% YoY
ALVR's debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.